Human Antibody Core

人类抗体核心设施基于俄克拉荷马州开发的技术 医学研究基金会。该技术有助于产生完全人的、全长的、抗原特异性的 克隆抗体这个过程可以在感染后28天内完成， 免疫并产生任何所需IgG亚类的全长、适当配对的抗体。 作为一个核心设施，我们已经生产了人类单克隆抗体用于各种目的，包括新的 诊断，被动免疫治疗，最重要的是，了解人类对 预防针我们目前拥有超过九百种单克隆抗体的库。已知特异性 包括季节性和大流行性H1N1、H3N2和B流感毒株、S.荚膜肺炎 多糖、狂犬病病毒和牛痘病毒以及炭疽保护性抗原（PA）。特别是我们的抗体 炭疽保护性抗原（PA），来自接种炭疽疫苗的个体 (AVA)的复杂构象表位结合的两种抗体， PA在体外和体内均表现出对致死毒素攻击的保护作用。我们的核心设施 作为合作中心的成员， 人类免疫学在过去的六年里。

The Human Antibody Core Facility is based on a technology that was developed at the Oklahoma Medical Research Foundation. The technology facilitates the production of fully human, full-length, antigen-specific monoclonal antibodies. The process can be completed in as little as 28 days post infection or immunization and creates full-length, properly paired antibodies of any desired IgG subclass. As a core facility, we have produced human monoclonals for a variety of purposes including novel diagnostics, passive immunotherapeutics and most importantly, understanding human immune responses to vaccination. We currently have a library of over nine hundred monoclonal antibodies. Known specificities include seasonal and pandemic H1N1, H3N2 and B influenza strains, S. pneumoniae capsular polysaccharide, rabies and vaccinia virus, and anthrax protective antigen (PA). In particular, our antibodies to anthrax protective antigen (PA), derived from an individual vaccinated with Anthrax Vaccine Absorbed (AVA), were carefully characterized, and two antibodies which bound to complex conformational epitopes of PA were shown to be protective against lethal toxin challenge both in vitro and in vivo. Our core facility produced these anti-PA monoclonals with previous funding as a member of the Cooperative Centers for Human Immunology during the last six years.